295 related articles for article (PubMed ID: 37541772)
1. CRIP1 fosters MDSC trafficking and resets tumour microenvironment via facilitating NF-κB/p65 nuclear translocation in pancreatic ductal adenocarcinoma.
Liu X; Tang R; Xu J; Tan Z; Liang C; Meng Q; Lei Y; Hua J; Zhang Y; Liu J; Zhang B; Wang W; Yu X; Shi S
Gut; 2023 Nov; 72(12):2329-2343. PubMed ID: 37541772
[TBL] [Abstract][Full Text] [Related]
2. CD200 promotes immunosuppression in the pancreatic tumor microenvironment.
Choueiry F; Torok M; Shakya R; Agrawal K; Deems A; Benner B; Hinton A; Shaffer J; Blaser BW; Noonan AM; Williams TM; Dillhoff M; Conwell DL; Hart PA; Cruz-Monserrate Z; Bai XF; Carson WE; Mace TA
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581043
[TBL] [Abstract][Full Text] [Related]
3. Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/MyD88/AKT/NF-κB pathway in pancreatic cancer.
Yin H; Pu N; Chen Q; Zhang J; Zhao G; Xu X; Wang D; Kuang T; Jin D; Lou W; Wu W
Cell Death Dis; 2021 Oct; 12(11):1033. PubMed ID: 34718325
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3.
Trovato R; Fiore A; Sartori S; Canè S; Giugno R; Cascione L; Paiella S; Salvia R; De Sanctis F; Poffe O; Anselmi C; Hofer F; Sartoris S; Piro G; Carbone C; Corbo V; Lawlor R; Solito S; Pinton L; Mandruzzato S; Bassi C; Scarpa A; Bronte V; Ugel S
J Immunother Cancer; 2019 Sep; 7(1):255. PubMed ID: 31533831
[TBL] [Abstract][Full Text] [Related]
5. Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.
Zhang X; Lao M; Xu J; Duan Y; Yang H; Li M; Ying H; He L; Sun K; Guo C; Chen W; Jiang H; Zhang X; Bai X; Liang T
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35260434
[TBL] [Abstract][Full Text] [Related]
6. Regnase-1 downregulation promotes pancreatic cancer through myeloid-derived suppressor cell-mediated evasion of anticancer immunity.
Okabe J; Kodama T; Sato Y; Shigeno S; Matsumae T; Daiku K; Sato K; Yoshioka T; Shigekawa M; Higashiguchi M; Kobayashi S; Hikita H; Tatsumi T; Okamoto T; Satoh T; Eguchi H; Akira S; Takehara T
J Exp Clin Cancer Res; 2023 Oct; 42(1):262. PubMed ID: 37814340
[TBL] [Abstract][Full Text] [Related]
7. CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3/NF-κB/SDF-1α axis to enhance efficacy against pancreatic cancer.
Sun R; Sun Y; Wu C; Liu Y; Zhou M; Dong Y; Du G; Luo H; Shi B; Jiang H; Li Z
Mol Ther; 2023 Nov; 31(11):3193-3209. PubMed ID: 37735875
[TBL] [Abstract][Full Text] [Related]
8. circCUL2 induces an inflammatory CAF phenotype in pancreatic ductal adenocarcinoma via the activation of the MyD88-dependent NF-κB signaling pathway.
Zheng S; Hu C; Lin H; Li G; Xia R; Zhang X; Su D; Li Z; Zhou Q; Chen R
J Exp Clin Cancer Res; 2022 Feb; 41(1):71. PubMed ID: 35189958
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer.
Kajiwara Y; Tazawa H; Yamada M; Kanaya N; Fushimi T; Kikuchi S; Kuroda S; Ohara T; Noma K; Yoshida R; Umeda Y; Urata Y; Kagawa S; Fujiwara T
Cancer Immunol Immunother; 2023 May; 72(5):1285-1300. PubMed ID: 36436021
[TBL] [Abstract][Full Text] [Related]
10. Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy.
Zhou J; Liu M; Sun H; Feng Y; Xu L; Chan AWH; Tong JH; Wong J; Chong CCN; Lai PBS; Wang HK; Tsang SW; Goodwin T; Liu R; Huang L; Chen Z; Sung JJ; Chow KL; To KF; Cheng AS
Gut; 2018 May; 67(5):931-944. PubMed ID: 28939663
[TBL] [Abstract][Full Text] [Related]
11. Hyper-O-GlcNAcylation is anti-apoptotic and maintains constitutive NF-κB activity in pancreatic cancer cells.
Ma Z; Vocadlo DJ; Vosseller K
J Biol Chem; 2013 May; 288(21):15121-30. PubMed ID: 23592772
[TBL] [Abstract][Full Text] [Related]
12. Metallothionein-1G suppresses pancreatic cancer cell stemness by limiting activin A secretion
Li K; Zhang Z; Mei Y; Yang Q; Qiao S; Ni C; Yao Y; Li X; Li M; Wei D; Fu W; Guo X; Huang X; Yang H
Theranostics; 2021; 11(7):3196-3212. PubMed ID: 33537082
[TBL] [Abstract][Full Text] [Related]
13. E3 ligase TRIM28 promotes anti-PD-1 resistance in non-small cell lung cancer by enhancing the recruitment of myeloid-derived suppressor cells.
Liang M; Sun Z; Chen X; Wang L; Wang H; Qin L; Zhao W; Geng B
J Exp Clin Cancer Res; 2023 Oct; 42(1):275. PubMed ID: 37865804
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer.
Takeuchi S; Baghdadi M; Tsuchikawa T; Wada H; Nakamura T; Abe H; Nakanishi S; Usui Y; Higuchi K; Takahashi M; Inoko K; Sato S; Takano H; Shichinohe T; Seino K; Hirano S
Cancer Res; 2015 Jul; 75(13):2629-40. PubMed ID: 25952647
[TBL] [Abstract][Full Text] [Related]
15. Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenvironment in pancreatic ductal adenocarcinoma.
Graziano V; Dannhorn A; Hulme H; Williamson K; Buckley H; Karim SA; Wilson M; Lee SY; Kaistha BP; Islam S; Thaventhiran JED; Richards FM; Goodwin R; Brais R; Morton JP; Dovedi SJ; Schuller AG; Eyles J; Jodrell DI
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37553182
[TBL] [Abstract][Full Text] [Related]
16. HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer.
Zhou Y; Jin X; Yu H; Qin G; Pan P; Zhao J; Chen T; Liang X; Sun Y; Wang B; Ren D; Zhu S; Wu H
Theranostics; 2022; 12(5):2080-2094. PubMed ID: 35265200
[No Abstract] [Full Text] [Related]
17. Response to radiotherapy in pancreatic ductal adenocarcinoma is enhanced by inhibition of myeloid-derived suppressor cells using STAT3 anti-sense oligonucleotide.
Oweida AJ; Mueller AC; Piper M; Milner D; Van Court B; Bhatia S; Phan A; Bickett T; Jordan K; Proia T; Schulick R; Messersmith WA; Del Chiaro M; Clambey E; Gough MJ; Williams J; Hansen K; Goodman K; Karam SD
Cancer Immunol Immunother; 2021 Apr; 70(4):989-1000. PubMed ID: 33097963
[TBL] [Abstract][Full Text] [Related]
18. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
[TBL] [Abstract][Full Text] [Related]
19. The role of 2-arachidonoylglycerol in the regulation of the tumor-immune microenvironment in murine models of pancreatic cancer.
Qiu C; Yang L; Wang B; Cui L; Li C; Zhuo Y; Zhang L; Zhang S; Zhang Q; Wang X
Biomed Pharmacother; 2019 Jul; 115():108952. PubMed ID: 31078044
[TBL] [Abstract][Full Text] [Related]
20. Local and systemic immune profiles of human pancreatic ductal adenocarcinoma revealed by single-cell mass cytometry.
Brouwer TP; de Vries NL; Abdelaal T; Krog RT; Li Z; Ruano D; Fariña A; Lelieveldt BPF; Morreau H; Bonsing BA; Vahrmeijer AL; Koning F; de Miranda NFCC
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]